Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

KRYS Stock Forecast

Krystal Biotech stock forecast is as follows: an average price target of $191.00 (represents a 7.24% upside from KRYS’s last price of $178.10) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

KRYS Price Target

The average price target for Krystal Biotech (KRYS) is $191.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $220.00 to $133.00. This represents a potential 7.24% upside from KRYS's last price of $178.10.

KRYS Analyst Ratings

Buy

According to 8 Wall Street analysts, Krystal Biotech's rating consensus is 'Buy'. The analyst rating breakdown for KRYS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Krystal Biotech Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 11, 2024	Dae Gon Ha	Stifel Nicolaus	$220.00	$185.00	18.92%	23.53%
Sep 02, 2024	Alec Stranahan	Bank of America Securities	$205.00	$195.12	5.06%	15.10%
Aug 12, 2024	Gavin Clark-Gartner	Evercore ISI	$206.00	$182.17	13.08%	15.67%
Apr 15, 2024	Dae Gon Ha	Stifel Nicolaus	$204.00	$169.75	20.18%	14.54%
Nov 07, 2022	Geulah Livshits	Chardan Capital	$133.00	$78.05	70.40%	-25.32%
Aug 08, 2022	Geulah Livshits	Chardan Capital	$130.00	$82.40	57.77%	-27.01%

Row per page

Go to

The latest Krystal Biotech stock forecast, released on Sep 11, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $220.00, which represents a 18.92% increase from the stock price at the time of the forecast ($185.00), and a 23.53% increase from KRYS last price ($178.10).

Krystal Biotech Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	4
Avg Price Target	-	$212.50	$208.75
Last Closing Price	$178.10	$178.10	$178.10
Upside/Downside	-100.00%	19.31%	17.21%

In the current month, the average price target of Krystal Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Krystal Biotech's last price of $178.10. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 04, 2024	Citigroup	Neutral	Neutral	Hold
Sep 11, 2024	Wedbush	Underperform	Underperform	Hold
Sep 11, 2024	National Securities Corporation	Buy	Buy	Hold
Sep 11, 2024	BMO Capital	Outperform	Outperform	Hold
Aug 28, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 12, 2024	Evercore ISI	Outperform	Outperform	Hold
Aug 05, 2024	Citigroup	Buy	Neutral	Downgrade
Feb 27, 2024	Guggenheim	Buy	Buy	Hold
Feb 27, 2024	Citigroup	Buy	Buy	Hold
May 22, 2023	Barclays	Buy	Buy	Hold

Row per page

Go to

Krystal Biotech's last stock rating was published by Citigroup on Nov 04, 2024. The company gave KRYS a "Neutral" rating, the same as its previous rate.

Krystal Biotech Financial Forecast

Krystal Biotech Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$8.56M	-	-	-
Avg Forecast	$226.17M	$195.91M	$165.57M	$145.26M	$142.10M	$143.72M	$138.26M	$102.78M	$124.28M	$114.83M	$109.18M	$92.13M	$91.55M	$82.94M	$65.27M	$47.37M	$28.55M	$6.29M	$142.86K	$663.41K	$290.29K
High Forecast	$233.99M	$202.68M	$171.30M	$150.29M	$147.02M	$148.69M	$143.04M	$106.33M	$128.58M	$118.80M	$112.96M	$95.31M	$93.59M	$83.56M	$65.27M	$47.37M	$44.93M	$6.29M	$147.80K	$796.10K	$348.34K
Low Forecast	$214.47M	$185.77M	$157.00M	$137.75M	$134.75M	$136.29M	$131.10M	$97.46M	$117.85M	$108.89M	$103.53M	$87.36M	$87.73M	$82.33M	$65.27M	$47.37M	$12.82M	$6.29M	$135.46K	$530.73K	$232.23K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	6	3	3	20	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.36%	-	-	-

Krystal Biotech's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.55M, with a low forecast of $12.82M, and a high forecast of $44.93M. KRYS's average Quarter revenue forecast represents a 233.70% increase compared to the company's last Quarter revenue of $8.56M (Sep 23).

Krystal Biotech EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	6	3	3	20	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-25.99M	$-23.12M	$-3.98M	$-2.13M
Avg Forecast	$196.91M	$170.56M	$144.15M	$126.47M	$123.72M	$125.13M	$120.37M	$89.48M	$108.20M	$99.97M	$95.06M	$80.21M	$79.71M	$72.21M	$56.83M	$41.24M	$24.86M	$5.48M	$124.38K	$-5.11M	$-3.18M
High Forecast	$203.72M	$176.46M	$149.14M	$130.84M	$128.00M	$129.46M	$124.54M	$92.58M	$111.94M	$103.43M	$98.34M	$82.98M	$81.48M	$72.75M	$56.83M	$41.24M	$39.12M	$5.48M	$128.68K	$-4.09M	$-2.54M
Low Forecast	$186.72M	$161.74M	$136.69M	$119.93M	$117.31M	$118.65M	$114.14M	$84.85M	$102.60M	$94.80M	$90.14M	$76.06M	$76.38M	$71.68M	$56.83M	$41.24M	$11.16M	$5.48M	$117.94K	$-6.14M	$-3.81M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.74%	-185.87%	0.78%	0.67%

undefined analysts predict KRYS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Krystal Biotech's previous annual EBITDA (undefined) of $NaN.

Krystal Biotech Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	6	3	3	20	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$80.75M	$-41.77M	$-4.11M	$-2.15M
Avg Forecast	$83.28M	$67.03M	$50.60M	$50.04M	$39.49M	$41.99M	$40.19M	$25.25M	$41.12M	$37.98M	$36.03M	$31.92M	$35.35M	$29.71M	$21.91M	$7.96M	$-9.22M	$-35.92M	$-43.01M	$-4.61M	$-3.02M
High Forecast	$87.02M	$70.05M	$52.87M	$52.29M	$41.27M	$43.87M	$42.00M	$26.38M	$42.96M	$39.68M	$37.65M	$37.41M	$51.19M	$30.16M	$21.92M	$7.96M	$-354.56K	$-33.50M	$-40.12M	$-3.69M	$-2.42M
Low Forecast	$77.68M	$62.52M	$47.19M	$46.68M	$36.84M	$39.16M	$37.49M	$23.55M	$38.35M	$35.42M	$33.61M	$26.43M	$27.15M	$29.25M	$21.91M	$7.96M	$-16.84M	$-37.53M	$-44.95M	$-5.53M	$-3.63M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.25%	0.97%	0.89%	0.71%

Krystal Biotech's average Quarter net income forecast for Dec 23 is $-9.22M, with a range of $-16.84M to $-354.56K. KRYS's average Quarter net income forecast represents a -111.42% decrease compared to the company's last Quarter net income of $80.75M (Sep 23).

Krystal Biotech SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	6	3	3	20	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$23.70M	$24.04M	$1.53M	$757.00K
Avg Forecast	$268.73M	$232.77M	$196.73M	$172.60M	$168.84M	$170.77M	$164.28M	$122.12M	$147.66M	$136.44M	$129.73M	$109.46M	$108.78M	$98.55M	$77.56M	$56.28M	$33.92M	$7.48M	$169.74K	$775.15K	$339.18K
High Forecast	$278.03M	$240.82M	$203.53M	$178.57M	$174.68M	$176.68M	$169.96M	$126.34M	$152.77M	$141.16M	$134.21M	$113.25M	$111.20M	$99.28M	$77.56M	$56.28M	$53.38M	$7.48M	$175.61K	$930.18K	$407.01K
Low Forecast	$254.83M	$220.73M	$186.55M	$163.67M	$160.10M	$161.93M	$155.77M	$115.80M	$140.02M	$129.38M	$123.01M	$103.80M	$104.24M	$97.83M	$77.56M	$56.28M	$15.23M	$7.48M	$160.96K	$620.12K	$271.34K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.17%	141.60%	1.97%	2.23%

Krystal Biotech's average Quarter SG&A projection for Dec 23 is $33.92M, based on 6 Wall Street analysts, with a range of $15.23M to $53.38M. The forecast indicates a 43.16% rise compared to KRYS last annual SG&A of $23.70M (Sep 23).

Krystal Biotech EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	6	3	3	20	15
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.88	$-1.62	$-0.29	$-0.21
Avg Forecast	$2.79	$2.24	$1.69	$1.67	$1.32	$1.40	$1.34	$0.84	$1.38	$1.27	$1.21	$1.07	$1.18	$0.99	$0.73	$0.27	$-0.31	$-1.20	$-1.44	$-0.33	$-0.67
High Forecast	$2.91	$2.34	$1.77	$1.75	$1.38	$1.47	$1.40	$0.88	$1.44	$1.33	$1.26	$1.25	$1.71	$1.01	$0.73	$0.27	$-0.01	$-1.12	$-1.34	$-0.33	$-0.54
Low Forecast	$2.60	$2.09	$1.58	$1.56	$1.23	$1.31	$1.25	$0.79	$1.28	$1.18	$1.12	$0.88	$0.91	$0.98	$0.73	$0.27	$-0.56	$-1.26	$-1.50	$-0.33	$-0.81
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.40%	1.13%	0.88%	0.31%

According to 6 Wall Street analysts, Krystal Biotech's projected average Quarter EPS for Dec 23 is $-0.31, with a low estimate of $-0.56 and a high estimate of $-0.01. This represents a -110.70% decrease compared to KRYS previous annual EPS of $2.88 (Sep 23).

Krystal Biotech Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RGNX	REGENXBIO	$9.63	$32.00	232.29%	Buy
APLS	Apellis Pharmaceuticals	$27.49	$74.50	171.01%	Buy
MGTX	MeiraGTx	$5.82	$9.00	54.64%	Buy
KRYS	Krystal Biotech	$178.10	$191.00	7.24%	Buy
DCPH	Deciphera Pharmaceuticals	$25.59	$26.32	2.85%	Hold
RYTM	Rhythm Pharmaceuticals	$59.36	$55.20	-7.01%	Buy

KRYS Forecast FAQ

Is Krystal Biotech a good buy?

Yes, according to 8 Wall Street analysts, Krystal Biotech (KRYS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of KRYS's total ratings.

What is KRYS's price target?

Krystal Biotech (KRYS) average price target is $191 with a range of $133 to $220, implying a 7.24% from its last price of $178.1. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Krystal Biotech stock go up soon?

According to Wall Street analysts' prediction for KRYS stock, the company can go up by 7.24% (from the last price of $178.1 to the average price target of $191), up by 23.53% based on the highest stock price target, and down by -25.32% based on the lowest stock price target.

Can Krystal Biotech stock reach $300?

KRYS's average twelve months analyst stock price target of $191 does not support the claim that Krystal Biotech can reach $300 in the near future.

What are Krystal Biotech's analysts' financial forecasts?

Krystal Biotech's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $526.86M (high $545.08M, low $499.6M), average EBITDA is $458.7M (high $474.57M, low $434.96M), average net income is $146.91M (high $153.52M, low $137.03M), average SG&A $626M (high $647.66M, low $593.61M), and average EPS is $4.91 (high $5.13, low $4.58). KRYS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $732.91M (high $758.26M, low $694.99M), average EBITDA is $638.09M (high $660.17M, low $605.07M), average net income is $250.95M (high $262.24M, low $234.07M), average SG&A $870.83M (high $900.95M, low $825.77M), and average EPS is $8.39 (high $8.77, low $7.83).

Did the KRYS's actual financial results beat the analysts' financial forecasts?

Based on Krystal Biotech's last annual report (Dec 2023), the company's revenue was $50.7M, beating the average analysts forecast of $34.99M by 44.91%. Apple's EBITDA was $-110M, missing the average prediction of $30.46M by -460.23%. The company's net income was $10.93M, missing the average estimation of $-88.149M by -112.40%. Apple's SG&A was $98.4M, beating the average forecast of $41.57M by 136.71%. Lastly, the company's EPS was $0.0004, missing the average prediction of $-2.948 by -100.01%. In terms of the last quarterly report (Sep 2023), Krystal Biotech's revenue was $8.56M, beating the average analysts' forecast of $6.29M by 35.97%. The company's EBITDA was $-25.993M, missing the average prediction of $5.48M by -574.47%. Krystal Biotech's net income was $80.75M, missing the average estimation of $-35.917M by -324.81%. The company's SG&A was $23.7M, beating the average forecast of $7.48M by 216.95%. Lastly, the company's EPS was $2.88, missing the average prediction of $-1.201 by -339.77%